IM Cannabis Corp. (CSE: IMCC) (Nasdaq: IMCC) is an international cannabis company specializing in providing premium medical cannabis products to patients in Israel and Germany. The company operates a transnational ecosystem powered by a data-driven approach and a globally sourced product supply chain. IM Cannabis leverages a commercial relationship with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients in Israel, utilizing proprietary data and patient insights. In Israel, the company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs to ensure safe delivery and quality control throughout the supply chain. In Germany, IM Cannabis distributes medical cannabis products to pharmacies through its subsidiary Adjupharm GmbH.
IM Cannabis recently exited operations in Canada to concentrate on sustainable and profitable growth in the Israeli and German markets. The company cultivates an unwavering commitment to responsible growth and compliance within the strictest regulatory environments. With the anticipated medical cannabis regulatory reform in Israel, scheduled for implementation in December 2023 but delayed due to the ongoing conflict, IM Cannabis expects significant growth in patient numbers and potential export opportunities to Europe through EU-GMP certification.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.